Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction.

Literature DB >> 33653703

Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction.

Sam Straw¹, Melanie McGinlay², Klaus K Witte³.

Abstract

Entities: Chemical

Keywords: clinical; heart failure; pharmacology; systolic

Mesh：

Substances：
Cardiovascular Agents

Year: 2021 PMID： 33653703 PMCID： PMC7929859 DOI： 10.1136/openhrt-2021-001585

Source DB: PubMed Journal: Open Heart ISSN： 2053-3624

× No keyword cloud information.

29 in total

1. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.

Authors: Rolf Wachter; Michele Senni; Jan Belohlavek; Ewa Straburzynska-Migaj; Klaus K Witte; Zhanna Kobalava; Candida Fonseca; Eva Goncalvesova; Yuksel Cavusoglu; Alberto Fernandez; Said Chaaban; Ellen Bøhmer; Anne-Catherine Pouleur; Christian Mueller; Christophe Tribouilloy; Eva Lonn; Jehad A L Buraiki; Jacek Gniot; Maria Mozheiko; Malgorzata Lelonek; Adele Noè; Heike Schwende; Weibin Bao; Dmytro Butylin; Domingo Pascual-Figal
Journal: Eur J Heart Fail Date: 2019-05-27 Impact factor: 15.534

2. Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry.

Authors: Abhinav Sharma; Xin Zhao; Bradley G Hammill; Adrian F Hernandez; Gregg C Fonarow; G Michael Felker; Clyde W Yancy; Paul A Heidenreich; Justin A Ezekowitz; Adam D DeVore
Journal: Circ Heart Fail Date: 2018-06 Impact factor: 8.790

3. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

Authors: John J V McMurray; Scott D Solomon; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Inder S Anand; Jan Bělohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andrej Dukát; Junbo Ge; Jonathan G Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Mark C Petrie; Pham N Vinh; Morten Schou; Sergey Tereshchenko; Subodh Verma; Claes Held; David L DeMets; Kieran F Docherty; Pardeep S Jhund; Olof Bengtsson; Mikaela Sjöstrand; Anna-Maria Langkilde
Journal: N Engl J Med Date: 2019-09-19 Impact factor: 91.245

4. Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients.

Authors: Chirik Wah Lau; Pieter Martens; Seppe Lambeets; Matthias Dupont; Wilfried Mullens
Journal: Acta Cardiol Date: 2018-11-25 Impact factor: 1.718

5. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

Authors: M R Bristow; E M Gilbert; W T Abraham; K F Adams; M B Fowler; R E Hershberger; S H Kubo; K A Narahara; H Ingersoll; S Krueger; S Young; N Shusterman
Journal: Circulation Date: 1996-12-01 Impact factor: 29.690

6. Mortality Reduction Associated With β-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes.

Authors: Klaus K Witte; Michael Drozd; Andrew M N Walker; Peysh A Patel; Jessica C Kearney; Sally Chapman; Robert J Sapsford; John Gierula; Maria F Paton; Judith Lowry; Mark T Kearney; Richard M Cubbon
Journal: Diabetes Care Date: 2017-10-05 Impact factor: 19.112

7. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras.

Authors: Richard M Cubbon; Christopher P Gale; Lorraine C Kearney; Clyde B Schechter; W Paul Brooksby; Jim Nolan; Keith A A Fox; Adil Rajwani; Wazir Baig; David Groves; Pauline Barlow; Anthony C Fisher; Phillip D Batin; Matthew B Kahn; Azfar G Zaman; Ajay M Shah; Jon A Byrne; Steven J Lindsay; Robert J Sapsford; Stephen B Wheatcroft; Klaus K Witte; Mark T Kearney
Journal: Circ Heart Fail Date: 2011-05-11 Impact factor: 8.790

8. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983

9. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine.

Authors: John J V McMurray; Milton Packer
Journal: Circulation Date: 2020-12-30 Impact factor: 29.690

10. Effect of disease-modifying agents and their association with mortality in multi-morbid patients with heart failure with reduced ejection fraction.

Authors: Sam Straw; Melanie McGinlay; Samuel D Relton; Aaron O Koshy; John Gierula; Maria F Paton; Michael Drozd; Judith E Lowry; Charlotte Cole; Richard M Cubbon; Klaus K Witte; Mark T Kearney
Journal: ESC Heart Fail Date: 2020-09-13

6 in total

1. Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction.

Authors: Sam Straw; Charlotte A Cole; Melanie McGinlay; Michael Drozd; Thomas A Slater; Judith E Lowry; Maria F Paton; Eylem Levelt; Richard M Cubbon; Mark T Kearney; Klaus K Witte; John Gierula
Journal: Clin Res Cardiol Date: 2022-07-04 Impact factor: 5.460

Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction.

1. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.

2. Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry.

3. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

4. Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients.

5. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

6. Mortality Reduction Associated With β-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes.

7. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras.

9. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine.

10. Effect of disease-modifying agents and their association with mortality in multi-morbid patients with heart failure with reduced ejection fraction.

1. Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction.

2. The 2021 European Heart Failure Guidelines: The Case for Personalised Therapeutics.

3. Overview of trials from AHA 2021.

Review 4. 'Acute Heart Failure': Should We Abandon the Term Altogether?

5. SGLT2 Inhibitors and Ketone Metabolism in Heart Failure.

Review 6. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction.